No abstract

No abstract

COVID-19 are an unprecedented challenge for healthcare providers; there are no approved treatments for this disease, nor are there no approved vaccines. The sources of infection of novel coronavirus detected mainly from animals to humans or infected human to healthy human through respiratory droplets and long contact period are the most prominent way of transmission. Coronaviruses are structurally large-sized single-stranded RNA viruses. The capability of regular therapies is constantly fading away exactly in case of coronavirus due to the modiϑication of new strain, which could be certainly due to speedy adaptation in a protein sequence. The scientist should understand the pandemic situation of virus infection, also as they ought to identify the newest pathway research to regulate the virus infection. Developing new and smart strategies for drugs already in the development pipeline or already exiting drug can be treating diseases in patients could be useful to ϑight against COVID-19. In the last few years, several new smart drug delivery approaches made the changeover from the laboratory development to clinical applications. At present technology, researchers provide effective and low toxicity drug delivery when compared with classical delivery. This approach will be a great opportunity for the scientist to work and update preclinical research of advance drug delivery systems to cloneable and convertible production to the human trial success rate. In conclusion, by understanding the new drug delivery research approaches for antiviral therapy are increases to produce safe and high-quality therapies at reasonable costs.

No abstract

SARS CoV 2 (severe acute respiratory syndrome novel corona virus-2) to which the world paid the complete attention to face the Global Emergency Alert. COVID 19 was first identified in Wuhan, province in China on December, 2020. The virus was originated from the Bats and transmitted through other intermediary animals. There are around 12.7 lakhs reported cases and more than 69.4 thousands deaths (06/04/2020) which pave the way for having the health crises in the entire world’s population. The governing bodies of the various countries are quarantining their people to avoid the various stages of CoV spreading. Compared to the SARS CoV (severe acute respiratory syndrome coronavirus) and MERS CoV (Middle East respiratory syndrome coronavirus), the fatality rate was lower. But it provides the major impacts on elder population (fatality rate more than 40-50 %). Normal/ low white cell counts with elevated CRP (C-reactive protein ) severs as the laboratory findings for the SARS CoV 2 with the symptoms of cough, sneeze, difficulties in breathing and fever followed by ARDS (Acute respiratory distress syndrome) and multi organ dysfunction. By complete understanding of CoV 2 Pathogenesis, presently many drugs are repositioning to completely eradicate the COVID 19. So many drugs are under clinical trials in which the Hydroxychloroquine produces the greater effects on SARS CoV. Likewise many drugs are subjected to this mega clinical trial by repositioning the drugs.  AYUSH recommends some of the prophylactics and dietary supplements for the COVID 19. This global emergency was not only for the researchers but also all professionals and their impact to the world’s developed and developing countries still unknown.